RESUMEN
A dual-detection technique, consisting of a combination of reversed-phase high-performance liquid chromatography and on-line detection of elemental boron in the column effluents by inductively coupled plasma optical emission spectrometry, was tested for drug analysis. The method was applied to assessing the chemical purity of p-boronophenylalanine (BPA), isotopically enriched in 10B. This compound is employed as a fructose complex solution for biodistribution studies in laboratory and clinical trials of boron neutron capture therapy. Besides the determination of the content of BPA, required for chemical quality controls of solutions of the complex used for infusions, resolution of mixtures of BPA and two usually accompanying residual impurities (phenylalanine and tyrosine) was achieved with UV detection. The limits of detection (in solution) were 1.5 and 0.6 ng ml-1, respectively. In addition, by monitoring a sensitive-element emission wavelength it was possible to jointly observe the elution of boron-containing compounds that may be transparent to UV radiation or to confirm the presence of boron in potential impurities accompanying the drug. Those impurities may arise from the BPA synthesis or may be produced by degradation during the aging of the solutions. Chromatographic peaks corresponding to the amino acids and also to a related inorganic compound were detected in BPA-fructose complex solutions that were stored for different times and under different conditions. An increase in the areas of the peaks attributed to tyrosine and phenylalanine was observed for BPA-fructose solutions stored refrigerated for 1 month to 1 year, suggesting that degradation processes able to reduce the amount of bioavailable BPA could be active.